Case studies from the methodology in practice.
Three patients Dr. Lorenzato worked with personally, before the system was a product. The cases are presented in full so a treating oncologist can evaluate them. The caveats are presented in full because the cases are real and the reader deserves the math.
Last reviewed: by Dr. Lorenzato
Please read this before the cases.
n = 3. These are three patients Dr. Lorenzato treated personally before the methodology was implemented as a product. They are not a clinical trial. They are not a statistically representative sample. Outcomes from these cases do not predict outcomes for any other patient. Cancer biology is complex; treatments interact in ways that differ from person to person; we do not guarantee results. The cases are documented here so a reader can evaluate the methodology against real cases — not as a sales promise about your own.
Example A — Rare metastatic thymoma
This patient was trained in risk-benefit analysis. She had been evaluated at Stanford, MD Anderson, Moffitt, Chicago hospitals, and NIH. None of them had additional options for her cancer type.
What she valued was not credentials. It was a physician's willingness to engage: to spend more than 15 minutes, to map her cancer's specific defense network, to build something no institution had offered her.
Outcome: 95% tumor reduction. She died years later from complications of chemotherapy. Not from the cancer.
The chemotherapy complications that ultimately took her life are themselves an outcome — we do not present this case as a clean win. The decision to pursue aggressive treatment was hers and her oncologist's. The protocol contributed to the tumor response that her primary care, before our involvement, had been told was not possible.
Example B — Terminal prognosis, 12-month estimate
This patient was given 12 months to live. He started reading the studies behind the first recommendations and became committed to the process. He followed the protocol through multiple treatment cycles, coordinating each Prime / Strike / Recover phase with his treating oncologist.
Outcome: He survived three years. He died of COVID-19, not cancer.
Three years versus twelve months is a sample of one. We do not claim that every patient with a twelve-month prognosis will see this. We do claim that engaging a cancer's defense network systematically — rather than letting it remain hidden — can change what the cancer can survive.
Example C — Metastatic prostate cancer
Ongoing protocol. The patient is currently in the middle of treatment cycles coordinated with the methodology.
Most recent assessment: low-or-no detectable cancer. This case is still in progress; we will update the status as the assessments continue.
We present this case while it is still active because we will present it whichever way it goes. If the cancer rebuilds defenses we did not anticipate, the patient relapses, or the response stalls, we will document that here. We will not retroactively hide an example that turns out badly.
What these cases have in common
Three different cancers. Three different defense networks. Three different protocols. What was the same:
- A licensed physician (Dr. Lorenzato) reviewed and signed every recommendation.
- Every intervention was tied to a specific defense mechanism the cancer was using to survive treatment, with the reviewed studies cited alongside.
- Timing was sequenced to the patient's treatment cycle — degrade defenses before treatment, coordinate with the strike, manage recovery after.
- The treating oncologist remained in charge of the standard-of-care treatment plan.
This is the same structure every Orchestrated Oncology Protocol Report follows today, generated by the multi-agent research engine and verified by Dr. Lorenzato before delivery.
What these cases are not
They are not a clinical trial. n=3, not randomized, not controlled, no statistical power. The mechanisms underlying the protocols are supported by reviewed research; the outcomes of these specific three cases are documented as observations, not as proof of effect for any other patient.
They are not a guarantee. Some patients do not respond. Some respond and then relapse. Some have adverse events. Cancer biology is complex and individual.
They are not a substitute for your oncologist. Every protocol is designed to complement standard care, not replace it. If a Protocol Report and your treating oncologist disagree, your treating oncologist is the person who should drive the decision.
Educational only. Not medical advice — review any change to your treatment with your treating oncologist.
Your case is yours. The methodology adapts.
Different cancers defend themselves differently. Different mutations. Different chokepoints. Every Protocol Report is built from scratch for the specific patient, the specific cancer, and the specific treatment cycle. Every protocol is reviewed and signed by Dr. Lorenzato before delivery. Every claim cites reviewed research your oncologist can verify.